Manchester and London, UK, 23 September, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced further positive data from its Orexin-1 programme to treat stress-related addictive disorders.
This data on the Company's first drug development programme, for treating stress related addictive disorders, is extremely encouraging. Having previously demonstrated industry-leading selectivity for this programme, the Company now reports that it has also demonstrated excellent drug-like properties in pharmacokinetic and pharmacodynamic studies, enabling the Company to rapidly progress towards the clinic. This result has been achieved within 12 months and is substantially faster and cheaper compared to traditional pharmaceutical development.
This rapid progress of the first C4XD programme demonstrates the platform is able to rapidly generate strong clinical candidates with good drug-like properties. This result gives the Company great confidence in its proprietary pipeline, including its GLP-1 programme targeting the $50bn diabetes market, and also validates the Company's technical superiority.
Piers Morgan, CEO, said "This further excellent result, following rapidly on our initial data in the Orexin-1 disease model, clearly shows the enormous advantage of C4XD's technology, positioning us to rapidly develop highly differentiated drugs in mutli-billlion dollar markets with high unmet needs."
He continued, "Using our understanding of molecular shapes, C4XD has built a strong pipeline using our proprietary platform that can intelligently design safer, better solutions to targets that industry has struggled to address. Importantly, we have shown our technology enables us to progress development significantly faster and much more cheaply than would be possible relying on traditional techniques alone."
C4XD has the only technology in the world that can generate accurate, experimentally-derived dynamic solution 3D structures of drug molecules in just a matter of days. It can be used in conjunction with existing technologies for structure-based drug design and can make a particularly high impact when protein crystallography is not routinely available, as is the case for GPCRs and ion channels.
The technology can also be applied to help identify and generate novel crystal polymorph forms, with exciting potential applications in the life cycle management of existing branded pharmaceuticals.